PDS Biotechnology Corp
NASDAQ:PDSB
Intrinsic Value
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PDSB.
PDS Biotechnology Corp's market capitalization is 105.9m USD.
PDSB stock price is 3.2 USD.
PDSB.
PDSB. Open DCF Valuation
PDSB. Open Relative Valuation
PDSB has upside potential of 359% compared to the average analyst price target.
Open Wall St Estimates
PDSB has negative Free Cash Flow for the last twelve months.
PDSB has negative Operating Income for the last twelve months.
PDSB has negative Net Income for the last twelve months.
PDSB's D/E (Debt to Equity) is very low and is equal to 0.75.
PDSB's long-term assets (59m USD) exceed its long-term liabilties (33m USD).
PDSB's ROE (Return on Equity) has significantly decreased in the last 3 years from -63% to -122%, and is approaching profitability.
PDSB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 327% to 3 871%.
PDSB's ROE (Return on Equity) for the past 12 months is negative and is equal to -122%.
PDSB's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 3 871%.
PDSB has negative Net Debt. This means that the company has more cash and short-term investments (57m USD) than debt (20m USD).
PDSB has negative three-year average ROE (Return on Equity): -71%. The company is not efficient at transforming stockholders' equity into net income.
PDSB has very high three-year average ROIC (Return on Invested Capital): 8 185%. The company is very efficient at using invested capital to generate operating income.
PDSB's short-term assets (59m USD) exceed its short-term liabilties (14m USD).
PDSB's Altman Z-Score is very low and is equal to -3.06.
PDSB doesn't generate enough operating income (-43m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
PDS Biotechnology Corp
Balance Sheet Decomposition
PDS Biotechnology Corp
| Current Assets | 59.1m |
| Cash & Short-Term Investments | 56.6m |
| Other Current Assets | 2.5m |
| Non-Current Assets | 335k |
| PP&E | 335k |
| Other Non-Current Assets | -10 |
| Current Liabilities | 13.6m |
| Accounts Payable | 7m |
| Accrued Liabilities | 2.4m |
| Other Current Liabilities | 4.2m |
| Non-Current Liabilities | 19.6m |
| Long-Term Debt | 19.6m |
| Other Non-Current Liabilities | -10 |
Earnings Waterfall
PDS Biotechnology Corp
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-43m
USD
|
|
Operating Income
|
-43m
USD
|
|
Other Expenses
|
103k
USD
|
|
Net Income
|
-42.9m
USD
|
Free Cash Flow Analysis
PDS Biotechnology Corp
PDSB Profitability Score
Profitability Due Diligence
PDS Biotechnology Corp's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
PDS Biotechnology Corp's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
PDSB Solvency Score
Solvency Due Diligence
PDS Biotechnology Corp's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
PDS Biotechnology Corp's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PDSB Price Targets Summary
PDS Biotechnology Corp
According to Wall Street analysts, the average 1-year price target for
PDSB
is 14.69 USD
with a low forecast of 5.05 USD and a high forecast of 22.05 USD.
Ownership
PDSB Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PDSB Price
PDS Biotechnology Corp
| Average Annual Return | 56.34% |
| Standard Deviation of Annual Returns | 146.42% |
| Max Drawdown | -93% |
| Market Capitalization | 105.9m USD |
| Shares Outstanding | 31 107 800 |
| Percentage of Shares Shorted | 17.56% |
Company Profile
PDS Biotechnology Corp
Country
Industry
Market Cap
Dividend Yield
Description
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.
You don't have any saved screeners yet
